
Saraswati Sukumar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5103706/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Abstract P5-08-03: Intraductal administration of a Transferrin Receptor-directed immunotoxin eliminates ductal carcinoma in situ in preclinical mammary in-duct (MIND) models of breast cancer. Cancer Research, 2022, 82, P5-08-03-P5-08-03.	0.4	0
2	Functional Antagonism of Junctional Adhesion Molecule-A (JAM-A), Overexpressed in Breast Ductal Carcinoma In Situ (DCIS), Reduces HER2-Positive Tumor Progression. Cancers, 2022, 14, 1303.	1.7	2
3	Development of an Automated Liquid Biopsy Assay for Methylated Markers in Advanced Breast Cancer. Cancer Research Communications, 2022, 2, 391-401.	0.7	5
4	Capturing ctDNA from Unaltered Stationary and Flowing Plasma with dCas9. ACS Applied Materials & Interfaces, 2022, 14, 24113-24121.	4.0	5
5	Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer—a preclinical study. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	8
6	Intraductal administration of N-methyl-N-nitrosourea as a novel rodent mammary tumor model. Annals of Translational Medicine, 2021, 9, 576-576.	0.7	6
7	Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors. Clinical Epigenetics, 2021, 13, 104.	1.8	10
8	Automated and rapid detection of cancer in suspicious axillary lymph nodes in patients with breast cancer. Npj Breast Cancer, 2021, 7, 89.	2.3	6
9	CRYβB2 enhances tumorigenesis through upregulation of nucleolin in triple negative breast cancer. Oncogene, 2021, 40, 5752-5763.	2.6	6
10	High performance methylated DNA markers for detection of colon adenocarcinoma. Clinical Epigenetics, 2021, 13, 218.	1.8	5
11	HOX genes and the NF-κB pathway: A convergence of developmental biology, inflammation and cancer biology. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188450.	3.3	32
12	Characteristics and antitumor activity of polysorbate 80 curcumin micelles preparation by cloud point cooling. Journal of Drug Delivery Science and Technology, 2020, 59, 101871.	1.4	6
13	Breast-Specific Epigenetic Regulation of DeltaNp73 and Its Role in DNA-Damage-Response of BRCA1-Mutated Human Mammary Epithelial Cells. Cancers, 2020, 12, 2367.	1.7	3
14	Unpredicted central inversion in a sgRNA flanked by inverted repeats. Molecular Biology Reports, 2020, 47, 6375-6378.	1.0	1
15	Multiple roles of HOX proteins in Metastasis: Let me count the ways. Cancer and Metastasis Reviews, 2020, 39, 661-679.	2.7	19
16	Nanoparticle interactions with immune cells dominate tumor retention and induce T cell–mediated tumor suppression in models of breast cancer. Science Advances, 2020, 6, eaay1601.	4.7	107
17	Intraductal Therapy in Breast Cancer: Current Status and Future Prospective. Journal of Mammary Gland Biology and Neoplasia, 2020, 25, 133-143.	1.0	8
18	DNA methylation markers predict recurrence-free interval in triple-negative breast cancer. Npj Breast Cancer, 2020, 6, 3.	2.3	15

#	Article	IF	CITATIONS
19	Targeted nanopore sequencing with Cas9-guided adapter ligation. Nature Biotechnology, 2020, 38, 433-438.	9.4	286
20	HEYL Regulates Neoangiogenesis Through Overexpression in Both Breast Tumor Epithelium and Endothelium. Frontiers in Oncology, 2020, 10, 581459.	1.3	6
21	DNA Methylation Markers for Breast Cancer Detection in the Developing World. Clinical Cancer Research, 2019, 25, 6357-6367.	3.2	21
22	Validation of a low-cost, carbon dioxide-based cryoablation system for percutaneous tumor ablation. PLoS ONE, 2019, 14, e0207107.	1.1	8
23	Discovery of a Potent GLUT Inhibitor from a Library of Rapafucins by Using 3D Microarrays. Angewandte Chemie - International Edition, 2019, 58, 17158-17162.	7.2	22
24	Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ. Nature Communications, 2019, 10, 4182.	5.8	37
25	A biologic scaffold–associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy. Science Translational Medicine, 2019, 11, .	5.8	96
26	Intraductal fulvestrant for therapy of ERα-positive ductal carcinoma in situ of the breast: a preclinical study. Carcinogenesis, 2019, 40, 903-913.	1.3	17
27	Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008. Breast Cancer Research and Treatment, 2018, 167, 107-116.	1.1	14
28	Quantitation of DNA Methylation by Quantitative Multiplex Methylation-Specific PCR (QM-MSP) Assay. Methods in Molecular Biology, 2018, 1708, 473-496.	0.4	9
29	Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer. Breast Cancer Research, 2018, 20, 145.	2.2	18
30	Breast Hormone Concentrations in Random Fine-Needle Aspirates of Healthy Women Associate with Cytological Atypia and Gene Methylation. Cancer Prevention Research, 2018, 11, 557-568.	0.7	3
31	Quantitative phosphoproteomic analysis reveals reciprocal activation of receptor tyrosine kinases between cancer epithelial cells and stromal fibroblasts. Clinical Proteomics, 2018, 15, 21.	1.1	15
32	Inhibitors of <scp>STAT</scp> 3, βâ€catenin, and <scp>IGF</scp> â€1R sensitize mouse <scp>PIK</scp> 3 <scp>CA</scp> â€mutant breast cancer to <scp>PI</scp> 3K inhibitors. Molecular Oncology, 2017, 11, 552-566.	2.1	25
33	Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. Journal of Clinical Oncology, 2017, 35, 751-758.	0.8	110
34	Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis. Theranostics, 2017, 7, 1062-1071.	4.6	71
35	Mutational profiles of breast cancer metastases from a rapid autopsy series reveal multiple evolutionary trajectories. JCl Insight, 2017, 2, .	2.3	19
36	The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer. Oncotarget, 2017, 8, 2971-2983.	0.8	42

#	Article	IF	CITATIONS
37	The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression. Cellular Signalling, 2016, 28, 1502-1519.	1.7	29
38	The Widening Sphere of Influence of HOXB7 in Solid Tumors. Cancer Research, 2016, 76, 2857-2862.	0.4	30
39	Guidelines for the selection of functional assays to evaluate the hallmarks of cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 300-319.	3.3	89
40	Gene Methylation and Cytological Atypia in Random Fine-Needle Aspirates for Assessment of Breast Cancer Risk. Cancer Prevention Research, 2016, 9, 673-682.	0.7	9
41	HOXC10 Expression Supports the Development of Chemotherapy Resistance by Fine Tuning DNA Repair in Breast Cancer Cells. Cancer Research, 2016, 76, 4443-4456.	0.4	52
42	Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer. Cancer Research, 2016, 76, 2013-2024.	0.4	40
43	A Self-Folding Hydrogel <i>In Vitro</i> Model for Ductal Carcinoma. Tissue Engineering - Part C: Methods, 2016, 22, 398-407.	1.1	36
44	HOX genes: Major actors in resistance to selective endocrine response modifiers. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 105-110.	3.3	12
45	DNA promoter hypermethylation in nipple fluid: a potential tool for early breast cancer detection. Oncotarget, 2016, 7, 24778-24791.	0.8	24
46	Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer. Oncotarget, 2016, 7, 33306-33315.	0.8	25
47	Multiplexed detection of serological cancer markers with plasmon-enhanced Raman spectro-immunoassay. Chemical Science, 2015, 6, 3906-3914.	3.7	96
48	HOXB7 Promotes Malignant Progression by Activating the TGFÎ ² Signaling Pathway. Cancer Research, 2015, 75, 709-719.	0.4	54
49	Somatic Cell Fusions Reveal Extensive Heterogeneity in Basal-like Breast Cancer. Cell Reports, 2015, 11, 1549-1563.	2.9	57
50	HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance. Cancer Discovery, 2015, 5, 944-959.	7.7	72
51	Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate. Clinical Cancer Research, 2015, 21, 3263-3273.	3.2	129
52	Improvement of Stability and Efficacy of C16Y Therapeutic Peptide via Molecular Self-Assembly into Tumor-Responsive Nanoformulation. Molecular Cancer Therapeutics, 2015, 14, 2390-2400.	1.9	26
53	Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer. Molecular and Cellular Proteomics, 2015, 14, 2887-2900.	2.5	26
54	A pivotal role for HOXB7 protein in endocrine resistant breast cancer. Oncoscience, 2015, 2, 917-919.	0.9	9

#	Article	IF	CITATIONS
55	Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. Oncotarget, 2015, 6, 29143-29160.	0.8	44
56	Do Breast Cancer Cell Lines Provide a Relevant Model of the Patient Tumor Methylome?. PLoS ONE, 2014, 9, e105545.	1.1	20
57	A breast cancer cell microarray (CMA) as a rapid method to characterize candidate biomarkers. Cancer Biology and Therapy, 2014, 15, 1593-1599.	1.5	12
58	The Notch Pathway Inhibits TGFβ Signaling in Breast Cancer through HEYL-Mediated Crosstalk. Cancer Research, 2014, 74, 6509-6518.	0.4	27
59	Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer. Cancer Research, 2014, 74, 2160-2170.	0.4	149
60	Genetic and Phenotypic Diversity in Breast Tumor Metastases. Cancer Research, 2014, 74, 1338-1348.	0.4	161
61	Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis. Nature Communications, 2014, 5, 4715.	5.8	154
62	Combining the strength of genomics, nanoparticle technology, and direct intraductal delivery for breast cancer treatment. Breast Cancer Research, 2014, 16, 306.	2.2	5
63	Activation of diverse signalling pathways by oncogenic PIK3CA mutations. Nature Communications, 2014, 5, 4961.	5.8	72
64	Tissue Specific DNA Methylation in Normal Human Breast Epithelium and in Breast Cancer. PLoS ONE, 2014, 9, e91805.	1.1	23
65	Cytoplasmic mislocalization of overexpressed FOXF1 is associated with the malignancy and metastasis of colorectal adenocarcinomas. Experimental and Molecular Pathology, 2013, 94, 262-269.	0.9	17
66	Molecular Profiling of Human Mammary Gland Links Breast Cancer Risk to a p27+ Cell Population with Progenitor Characteristics. Cell Stem Cell, 2013, 13, 117-130.	5.2	72
67	Molecular Pathways: Current Role and Future Directions of the Retinoic Acid Pathway in Cancer Prevention and Treatment. Clinical Cancer Research, 2013, 19, 1651-1659.	3.2	175
68	Big Punches Come in Nanosizes for Chemoprevention. Cancer Prevention Research, 2013, 6, 1007-1010.	0.7	6
69	Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer. Clinical Cancer Research, 2013, 19, 4008-4016.	3.2	26
70	HOXB13 Mediates Tamoxifen Resistance and Invasiveness in Human Breast Cancer by Suppressing ERα and Inducing IL-6 Expression. Cancer Research, 2013, 73, 5449-5458.	0.4	80
71	Modeling precision treatment of breast cancer. Genome Biology, 2013, 14, R110.	13.9	264
72	HMGA1: A Master Regulator of Tumor Progression in Triple-Negative Breast Cancer Cells. PLoS ONE, 2013, 8, e63419.	1.1	106

#	Article	IF	CITATIONS
73	Loperamide, an FDA-Approved Antidiarrhea Drug, Effectively Reverses the Resistance of Multidrug Resistant MCF-7/MDR1 Human Breast Cancer Cells to Doxorubicin-Induced Cytotoxicity. Cancer Investigation, 2012, 30, 119-125.	0.6	23
74	Altered antisense-to-sense transcript ratios in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2820-2824.	3.3	54
75	Collagen I fiber density increases in lymph node positive breast cancers: pilot study. Journal of Biomedical Optics, 2012, 17, 116017.	1.4	95
76	MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. Modern Pathology, 2012, 25, 378-387.	2.9	67
77	The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the ECFR pathway. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2736-2741.	3.3	95
78	Intraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumors. Breast Cancer Research and Treatment, 2012, 135, 201-208.	1.1	21
79	Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: Implications for breast cancer chemoprevention in at-risk populations. Carcinogenesis, 2012, 33, 2242-2249.	1.3	53
80	Myeloid Progenitor Cells in the Premetastatic Lung Promote Metastases by Inducing Mesenchymal to Epithelial Transition. Cancer Research, 2012, 72, 1384-1394.	0.4	261
81	ADP Ribosylation by PARP-1 Suppresses HOXB7 Transcriptional Activity. PLoS ONE, 2012, 7, e40644.	1.1	12
82	Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients. International Journal of Cancer, 2012, 131, E1166-72.	2.3	49
83	The p53–p21WAF1 checkpoint pathway plays a protective role in preventing DNA rereplication induced by abrogation of FOXF1 function. Cellular Signalling, 2012, 24, 316-324.	1.7	32
84	Somatic mutations in the notch, NFâ€KB, PIK3CA, and hedgehog pathways in human breast cancers. Genes Chromosomes and Cancer, 2012, 51, 480-489.	1.5	58
85	Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nature Genetics, 2011, 43, 621-629.	9.4	1,080
86	Genome-wide Methylation Analysis Identifies Genes Specific to Breast Cancer Hormone Receptor Status and Risk of Recurrence. Cancer Research, 2011, 71, 6195-6207.	0.4	179
87	Methylated genes in breast cancer. Cancer Biology and Therapy, 2011, 11, 853-865.	1.5	44
88	Preclinical and Clinical Evaluation of Intraductally Administered Agents in Early Breast Cancer. Science Translational Medicine, 2011, 3, 106ra108.	5.8	66
89	Functional Activation of the Estrogen Receptor-α and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to Letrozole. Cancer Research, 2011, 71, 1893-1903.	0.4	147
90	Epigenetic Regulation of Cell Type–Specific Expression Patterns in the Human Mammary Epithelium. PLoS Genetics, 2011, 7, e1001369.	1.5	96

#	Article	IF	CITATIONS
91	Quantitative assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 457, 35-42.	1.4	9
92	Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases. Breast Cancer Research and Treatment, 2010, 123, 701-708.	1.1	66
93	Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women. Gynecologic Oncology, 2010, 118, 176-181.	0.6	30
94	Proteomic characterization of Her2/neuâ€overexpressing breast cancer cells. Proteomics, 2010, 10, 3800-3810.	1.3	32
95	Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature, 2010, 464, 1071-1076.	13.7	4,648
96	The Hox genes and their roles in oncogenesis. Nature Reviews Cancer, 2010, 10, 361-371.	12.8	685
97	Gene expression profiling of human breast tissue samples using SAGE-Seq. Genome Research, 2010, 20, 1730-1739.	2.4	35
98	Epigenetic Inactivation of the Potential Tumor Suppressor Gene <i>FOXF1</i> in Breast Cancer. Cancer Research, 2010, 70, 6047-6058.	0.4	81
99	Basal-like breast cancer displays distinct patterns of promoter methylation. Cancer Biology and Therapy, 2010, 9, 1017-1024.	1.5	34
100	Clonal selection in tamoxifen resistance. Cancer Biology and Therapy, 2010, 9, 725-727.	1.5	1
101	DNA methylation-related vitamin D receptor insensitivity in breast cancer. Cancer Biology and Therapy, 2010, 10, 44-53.	1.5	85
102	Store-Independent Activation of Orai1 by SPCA2 in Mammary Tumors. Cell, 2010, 143, 84-98.	13.5	254
103	BRCA1: linking HOX to breast cancer suppression. Breast Cancer Research, 2010, 12, 306.	2.2	7
104	Intraductal therapy for the prevention of breast cancer. Current Opinion in Investigational Drugs, 2010, 11, 646-52.	2.3	9
105	Hypermethylated Genes as Biomarkers of Cancer in Women with Pathologic Nipple Discharge. Clinical Cancer Research, 2009, 15, 3802-3811.	3.2	42
106	PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations. Proteins: Structure, Function and Bioinformatics, 2009, 75, 499-508.	1.5	21
107	MethySYBR, a Novel Quantitative PCR Assay for the Dual Analysis of DNA Methylation and CpG Methylation Density. Journal of Molecular Diagnostics, 2009, 11, 400-414.	1.2	36
108	Cell type-specific DNA methylation patterns in the human breast. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14076-14081.	3.3	210

#	Article	IF	CITATIONS
109	Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: Potential applications for diagnosis. Cancer Biology and Therapy, 2008, 7, 1398-1406.	1.5	25
110	A PET rat model for assessing the effectiveness of new chemotherapies. Cancer Biology and Therapy, 2008, 7, 538-539.	1.5	0
111	The Mammalian Ortholog of <i>Drosophila</i> MOF That Acetylates Histone H4 Lysine 16 Is Essential for Embryogenesis and Oncogenesis. Molecular and Cellular Biology, 2008, 28, 397-409.	1.1	194
112	Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal Metastases. Clinical Cancer Research, 2008, 14, 1938-1946.	3.2	193
113	SLITs Suppress Tumor Growth <i>In vivo</i> by Silencing <i>Sdf1/Cxcr4</i> within Breast Epithelium. Cancer Research, 2008, 68, 7819-7827.	0.4	117
114	Hoxb7 Inhibits Transgenic HER-2/neu–Induced Mouse Mammary Tumor Onset but Promotes Progression and Lung Metastasis. Cancer Research, 2008, 68, 3637-3644.	0.4	61
115	ETS genes in breast cancer: A step in the right direction. Cancer Biology and Therapy, 2007, 6, 83-84.	1.5	1
116	<i>HOXA5</i> Acts Directly Downstream of Retinoic Acid Receptor β and Contributes to Retinoic Acid–Induced Apoptosis and Growth Inhibition. Cancer Research, 2007, 67, 8007-8013.	0.4	66
117	A Role for the HOXB7 Homeodomain Protein in DNA Repair. Cancer Research, 2007, 67, 1527-1535.	0.4	79
118	A comparative study of korean with caucasian breast cancer reveals frequency of methylation in multiple genes correlates with breast cancer in young, ER, PR-negative breast cancer in korean women. Cancer Biology and Therapy, 2007, 6, 1114-1120.	1.5	23
119	Clostridium perfringens Enterotoxin as a Novel-Targeted Therapeutic for Brain Metastasis. Cancer Research, 2007, 67, 7977-7982.	0.4	67
120	Molecular Definition of Breast Tumor Heterogeneity. Cancer Cell, 2007, 11, 259-273.	7.7	1,273
121	The Genomic Landscapes of Human Breast and Colorectal Cancers. Science, 2007, 318, 1108-1113.	6.0	3,049
122	Benzoylphenylurea Sulfur Analogues with Potent Antitumor Activity. Journal of Medicinal Chemistry, 2006, 49, 2357-2360.	2.9	41
123	Two-color quantitative multiplex methylation-specific PCR. BioTechniques, 2006, 40, 210-219.	0.8	28
124	Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer. Cancer Biology and Therapy, 2006, 5, 281-286.	1.5	81
125	Overexpression of Glycosylphosphatidylinositol (GPI) Transamidase Subunits Phosphatidylinositol Glycan Class T and/or GPI Anchor Attachment 1 Induces Tumorigenesis and Contributes to Invasion in Human Breast Cancer. Cancer Research, 2006, 66, 9829-9836.	0.4	62
126	Mutational hotspot in Exon 20 of PIK3CA in breast cancer among singapore chinese. Cancer Biology and Therapy, 2006, 5, 544-548.	1.5	19

#	Article	IF	CITATIONS
127	Polyamine Analogues Down-regulate Estrogen Receptor α Expression in Human Breast Cancer Cells. Journal of Biological Chemistry, 2006, 281, 19055-19063.	1.6	37
128	Quantitative Multiplex Methylation-Specific PCR Analysis Doubles Detection of Tumor Cells in Breast Ductal Fluid. Clinical Cancer Research, 2006, 12, 3306-3310.	3.2	122
129	HOXB7, a Homeodomain Protein, Is Overexpressed in Breast Cancer and Confers Epithelial-Mesenchymal Transition. Cancer Research, 2006, 66, 9527-9534.	0.4	171
130	Ductal Access for Prevention and Therapy of Mammary Tumors. Cancer Research, 2006, 66, 638-645.	0.4	84
131	Epigenetic Biomarkers and Breast Cancer: Cause for Optimism. Clinical Cancer Research, 2006, 12, 6591-6593.	3.2	12
132	RUNX3 Is Frequently Inactivated by Dual Mechanisms of Protein Mislocalization and Promoter Hypermethylation in Breast Cancer. Cancer Research, 2006, 66, 6512-6520.	0.4	177
133	Of Snail, mice, and women. Cancer Cell, 2005, 8, 173-174.	7.7	26
134	Tumor-specific changes in mtDNA content in human cancer. International Journal of Cancer, 2005, 116, 920-924.	2.3	160
135	Identification of Biomarkers for Breast Cancer in Nipple Aspiration and Ductal Lavage Fluid. Clinical Cancer Research, 2005, 11, 8312-8320.	3.2	93
136	Role of p53/p21Waf1/Cip1 in the regulation of polyamine analogue-induced growth inhibition and cell death in human breast cancer cells. Cancer Biology and Therapy, 2005, 4, 1006-1013.	1.5	17
137	Identification of Transcriptional Targets of HOXA5. Journal of Biological Chemistry, 2005, 280, 19373-19380.	1.6	45
138	Quantitative Multiplex Methylation-Specific PCR Assay for the Detection of Promoter Hypermethylation in Multiple Genes in Breast Cancer. Cancer Research, 2004, 64, 4442-4452.	0.4	241
139	Alterations in Vascular Gene Expression in Invasive Breast Carcinoma. Cancer Research, 2004, 64, 7857-7866.	0.4	183
140	Very High Frequency of Hypermethylated Genes in Breast Cancer Metastasis to the Bone, Brain, and Lung. Clinical Cancer Research, 2004, 10, 3104-3109.	3.2	129
141	HOXA5-Induced Apoptosis in Breast Cancer Cells Is Mediated by Caspases 2 and 8. Molecular and Cellular Biology, 2004, 24, 924-935.	1.1	129
142	Estrogen Receptor/Progesterone Receptor-Negative Breast Cancers of Young African-American Women Have a Higher Frequency of Methylation of Multiple Genes than Those of Caucasian Women1. Clinical Cancer Research, 2004, 10, 2052-2057.	3.2	103
143	Coupling the Transcriptional Regulatory Action of Brn-3b to the Cell Cycle Clock. Cancer Biology and Therapy, 2004, 3, 324-325.	1.5	1
144	Hypermethylation in Histologically Distinct Classes of Breast Cancer. Clinical Cancer Research, 2004, 10, 5998-6005.	3.2	109

#	Article	IF	CITATIONS
145	Significant allelic loss of ANX7region (10q21) in hormone receptor negative breast carcinomas. Cancer Letters, 2004, 210, 239-244.	3.2	21
146	Clostridium perfringens Enterotoxin Elicits Rapid and Specific Cytolysis of Breast Carcinoma Cells Mediated through Tight Junction Proteins Claudin 3 and 4. American Journal of Pathology, 2004, 164, 1627-1633.	1.9	236
147	Novel agents for chemoprevention, screening methods, and sampling issues. Journal of Mammary Gland Biology and Neoplasia, 2003, 8, 75-89.	1.0	7
148	Role of homeobox genes in normal mammary gland development and breast tumorigenesis. Journal of Mammary Gland Biology and Neoplasia, 2003, 8, 159-175.	1.0	73
149	DNA methylation ofRASSF1A, HIN-1, RAR-?, Cyclin D2 andTwist inin situ and invasive lobular breast carcinoma. International Journal of Cancer, 2003, 107, 970-975.	2.3	242
150	Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene, 2003, 22, 2021-2033.	2.6	415
151	Methylation Profiling of Benign and Malignant Breast Lesions and Its Application to Cytopathology. Modern Pathology, 2003, 16, 1095-1101.	2.9	57
152	HOX Genes — Emerging Stars in Cancer. Cancer Biology and Therapy, 2003, 2, 524-525.	1.5	49
153	Mitoxantrone Mediates Demethylation and Re-Expression of Cyclin D2, Estrogen Receptor 14.3.3 Sigma In Breast Cancer Cells. Cancer Biology and Therapy, 2003, 2, 259-263.	1.5	27
154	Cyclin E Is a Target of WT1 Transcriptional Repression. Journal of Biological Chemistry, 2002, 277, 19627-19632.	1.6	39
155	The Role of WT1 in Oncogenesis: Tumor Suppressor or Oncogene?. International Journal of Hematology, 2002, 76, 117-126.	0.7	55
156	Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet, The, 2001, 357, 1335-1336.	6.3	324
157	Hypermethylation of 14-3-3 σ (stratifin) is an early event in breast cancer. Oncogene, 2001, 20, 3348-3353.	2.6	284
158	Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells. Oncogene, 2000, 19, 1556-1563.	2.6	188
159	Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature, 2000, 405, 974-978.	13.7	451
160	HOXA5 Regulates Expression of the Progesterone Receptor. Journal of Biological Chemistry, 2000, 275, 26551-26555.	1.6	68
161	Telomerase Activity and Prognosis in Primary Breast Cancers. Journal of Clinical Oncology, 1999, 17, 3075-3081.	0.8	52
162	Telomerase activity as a measure for monitoring radiocurability of tumor cells. FASEB Journal, 1999, 13, 1047-1054.	0.2	47

#	Article	IF	CITATIONS
163	Analysis of human transcriptomes. Nature Genetics, 1999, 23, 387-388.	9.4	719
164	Applications of telomerase research in the fight against cancer. Trends in Molecular Medicine, 1999, 5, 114-122.	2.6	37
165	Absence of TSG101 transcript abnormalities in human cancers. Oncogene, 1998, 16, 2815-2818.	2.6	12
166	Molecular cloning and chromosomal localization of Chinese hamster telomeric protein chTRF1. Its potential role in chromosomal instability. Oncogene, 1998, 17, 2137-2142.	2.6	24
167	Differential Effects of Wilms Tumor WT1 Splice Variants on the Insulin Receptor Promoter. Biochemical and Molecular Medicine, 1997, 62, 139-150.	1.5	21
168	Frequent activation of the Ki-ras oncogene at codon 12 inN-methyl-N-nitrosourea-induced rat prostate adenocarcinomas and neurogenic sarcomas. Molecular Carcinogenesis, 1991, 4, 362-368.	1.3	41
169	Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature, 1985, 315, 382-385.	13.7	872
170	Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature, 1983, 306, 658-661.	13.7	736
171	Eradication of microscopic hepatic metastases by active specific immunization. Cancer Immunology, Immunotherapy, 1983, 14, 151-154.	2.0	6
172	Active specific immunotherapy of guinea pigs with visceral tumor implants. Cancer Immunology, Immunotherapy, 1982, 12, 273.	2.0	4
173	A specific vaccine effective against stage I and stage II malignant disease in guinea pigs effect of variations in preparations and storage. Cancer Immunology, Immunotherapy, 1982, 14, 92-5.	2.0	Ο